Objective: We describe a technique to maintain amniotic fluid in fetuses with severe oligo-/anhydramnios secondary to lower urinary tract obstruction or fetal renal disease when urine production is inadequate to maintain a normal amniotic fluid volume (AFV). Methods: An amnioport was inserted into the amniotic space. The catheter was secured to prevent dislodgment and tunneled to a subcutaneous reservoir. The reservoir was accessed as necessary, infusing normal saline to maintain AFV. Pregnancy continued until term or indicated delivery. Results: Since 2010, 15 patients in this category were considered for an amnioport. Six chose comfort care and one elected percutaneous amnioinfusions. Nine amnioport procedures were performed in eight patients. There were no fetal deaths. All eight had successful restoration and maintenance of amniotic fluid. Delivery ranged from 9 to 96 days after placement (mean 63.7 days). One died due to unrecognized laryngeal web and another one died of pulmonary hypoplasia after preterm premature rupture of membranes. None of the remaining six had pulmonary hypoplasia. Three remain alive. Discussion: Severe oligo-/anhydramnios in the second trimester secondary to fetal anomalies is almost uniformly lethal due to pulmonary hypoplasia without restoration of amniotic fluid. The amnioport procedure may allow pulmonary survival but commits families to postnatal care decisions regarding pulmonary and renal complications.

Keywords:
Lower urinary tract obstruction, Fetal therapy, Oligohydramnios, Amnioinfusion, Fetal obstructive uropathy, Amnioport
1.
Baird JM, Johnson MF, Carr MC, Wilson RD, Hedrick HL, Pavlock C, Adzick NS: Long-term outcomes in children treated by prenatal vesicoamniotic shunting for lower urinary tract obstruction. Obstet Gynecol 2005;106:503-508.
2.
Elder JS, Duckett JW Jr, Snyder HM: Intervention for fetal obstructive uropathy: has it been effective? Lancet 1987;2:1007-1010.
3.
Craparo FJ, Rustico M, Tassis B, Coviello D, Nicolini U: Fetal serum β2-microglobulin before and after bladder shunting: a 2-step approach to evaluate fetuses with lower urinary tract obstruction. J Urol 2007;178:2576-2579.
4.
Crombleholme TM, Harrison MR, Golbus MS, Longaker MT, Langer JC, Callen PW, Anderson RL, Goldstein RB, Filly RA: Fetal intervention in obstructive uropathy: prognostic indicators and efficacy of intervention. Am J Obstet Gynecol 1990;162:1239-1244.
5.
Freedman AL, Johnson MP, Smith CA, Gonzalez R, Evans MI: Long-term outcome in children after antenatal intervention for obstructive uropathies. Lancet 1999;354:374-377.
6.
Holmes N, Harrison MR, Baskin LW: Fetal surgery for posterior urethral valves: long-term postnatal outcomes. Pediatrics 2001;108:E7.
7.
Warady BA, Neu AM, Schaefer F: Optimal care of the infant, child, and adolescent on dialysis: 2014 update. Am J Kidney Dis 2014;64:128-142.
8.
Harrison MR, Nakayama DK, Noall R, de Lorimier AA: Correction of congenital hydronephrosis in utero II. Decompression reverses the effects of obstruction on the fetal lung and urinary tract. J Pediatr Surg 1982;17:965-974.
9.
Harrison MR, Ross N, Noall R, de Lorimier AA: Correction of congenital hydronephrosis in utero. I. The model: fetal urethral obstruction produces hydronephrosis and pulmonary hypoplasia in fetal lambs. J Pediatr Surg 1983;18:247-256.
10.
Mercer BM: Preterm premature rupture of the membranes. Obstet Gynecol 2003;101:178-193.
11.
Ogunyemi D, Thompson W: A case controlled study of serial transabdominal amnioinfusions in the management of second trimester oligohydramnios due to premature rupture of membranes. Eur J Obstet Gynecol Reprod Biol 2002;102:167-172.
12.
Fisk NM, Ronderos-Dumit D, Soliani A, Nicolini U, Vaughan J, Rodec CH: Diagnostic and therapeutic transabdominal amnioinfusion in oligohydramnios. Obstet Gynecol 1991;78:270-278.
13.
De Santis M, Scavo M, Noia G, Masini L, Piersigilli F, Romagnoli C, Caruso A: Transabdominal amnioinfusion treatment of severe oligohydramnios in preterm premature rupture of membranes at less than 26 gestational weeks. Fetal Diagn Ther 2003;18:412-417.
14.
Tchirikov M, Steetskamp J, Hohmann M, Koelbl H: Long-term amnioinfusion through a subcutaneously implanted amniotic fluid replacement port system for treatment of PPROM in humans. Eur J Obstet Gynecol Reprod Biol 2010;152:30-33.
15.
Lantos JD, Warady BA: The evolving ethics of infant dialysis. Pediatr Nephrol 2013;28:1943-1947.
16.
Ledermann SE, Scanes ME, Fernando ON, Duffy PG, Madden SJ, Trompeter RS: Long-term outcome of peritoneal dialysis in infants. J Pediatr 2000;136:24-29.
17.
Carey WA, Talley LI, Sehring SA, Jaskula JM, Mathias RS: Outcomes of dialysis initiated during the neonatal period for treatment of end-stage renal disease: a North American Pediatric Renal Trials and Collaborative Studies special analysis. Pediatrics 2007;119:e468-e473.
18.
Nishimi S, Ishikawa K, Sasaki M, Furukawa H, Takada A, Chida S: Ability of a novel system for neonatal extracorporeal renal replacement therapy with an ultra-small volume circuit to remove solutes in vitro. Pediatr Nephrol 2016;31:493-500.
19.
Askenazi D, Ingram D, White S, Cramer M, Borasino S, Coghill C, Dill L, Tenney F, Feig D, Fathallah-Shaykh S: Smaller circuits for smaller patients: improving renal support therapy with Aquadex™. Pediatr Nephrol 2016;31:853-860.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.